The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat.
BACKGROUND
Anticipatory nausea (AN) experienced by chemotherapy patients is resistant to current anti-nausea treatments. In this study, the effect of manipulation of the endocannabinoid (EC) system on a rat model of nausea (conditioned gaping) was determined.


OBJECTIVE
The potential of cannabidiol (CBD) and the fatty acid amide hydrolase (FAAH) inhibitor, URB597 (URB) to reduce conditioned gaping in rats were evaluated.


METHODS
In each experiment, rats received four conditioning trials in which they were injected with lithium chloride immediately before placement in a distinctive odor-laced context. During testing, in experiment 1, rats were injected with vehicle (VEH), 1, 5 or 10 mg/kg CBD 30 min before placement in the context previously paired with nausea and in experiment 2, rats were injected with VEH, 0.1 or 0.3 mg/kg URB 2 h before placement in the context. Additional groups evaluated the ability of the CB(1) antagonist/inverse agonist, SR141716A, to reverse the suppressive effects of URB. Experiment 3 measured the potential of URB to interfere with the establishment of conditioned gaping.


RESULTS
When administered before testing, CBD (1 and 5, but not 10 mg/kg) and URB (0.3, but not 0.1 mg/kg) suppressed conditioned gaping. The effect of URB was reversed by pre-treatment with the CB(1) antagonist/inverse agonist, SR141716A. When administered before conditioning, URB also interfered with the establishment of conditioned gaping.


CONCLUSIONS
Manipulations of the EC system may have therapeutic potential in the treatment of AN.
Rock
Erin M
EM
Department of Psychology, University of Guelph, Guelph, ON, Canada.
Limebeer
Cheryl L
CL
Mechoulam
Raphael
R
Piomelli
Daniele
D
Parker
Linda A
LA
D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects; D001549:Benzamides / Q000494:pharmacology*; D002185:Cannabidiol / Q000008:administration & dosage / Q000494:pharmacology*; D002219:Carbamates / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D018021:Lithium Chloride; D008297:Male; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D051381:Rats; D020318:Rats, Long-Evans; D017207:Rats, Sprague-Dawley; D014840:Vomiting, Anticipatory / Q000139:chemically induced / Q000188:drug therapy*; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D000932:Antiemetics; D000970:Antineoplastic Agents; D001549:Benzamides; D002185:Cannabidiol; D002219:Carbamates; D018021:Lithium Chloride; D000099252:Fatty Acid Amide Hydrolases; C500528:cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester